| PATENT CLAIMS |
MAb that competes with MAb selected from group consisting of MAb 512-1-8 (ATCC HB12266), & MAb 50-1-3 (ATCC HB-
12267) for specific binding to human cytochrome p450 2D6 & specifically inhibits catalyzed metabolism of bufuralol human cytochrome P450 2D6 by > 75%, wherein the MAb of comprises a light chain variable domain having > 80% seq identity with the light chain variable domain of MAb selected from group consisting of MAb 512-1-8 (ATCC HB-12266) & MAb 50-1-3 (ATCC HB-12267), the % seq identity of the light chains being determined by alignment of AA by Kabat numbering; & the heavy chain variable domain having > 80% seq identity with the heavy chain variable domain of MAb selected from group consisting of MAb 512-1-8 (ATTC HB 12266) & MAb 50-1-3 (ATCC HB-12267) the % seq identity of heavy chains being determined by alignment of AA by Kabat numbering
|